Schwarz: The Omeprazole Opportunity

Germany's Schwarz has invested heavily in its transition from a marketing organization into a development-based firm. Higher-than expected windfall revenues from generic omeprazole increase its chances of a successful transformation.

Germany's Schwarz Pharma AG has accepted lower-than-average profits over the last few years as it transforms itself from a branded generics player and local co-marketer into a development-based firm. Realizing in the mid-90s that Big Pharma didn't need co-marketing partners any more, and that prices at home were spiraling downwards, Schwarz accepted just 3-4% annual growth for the sake of heavy investments into a development pipeline of its own.

Not that Schwarz is delving too deeply into development—simply to the depths of a risk-comfort zone that the family-controlled firm...

More from Business Strategy

More from In Vivo

Podcast: ADDF’s Karen Harris On Investing In Alzheimer’s Like A VC

 
• By 

A discussion with Karen Harris, CFO of the Alzheimer's Drug Discovery Foundation, about the foundation's investment strategy, biotech and investor sentiment at the recent BIO conference and what innovations give her hope for Alzheimer's patients.

Turning Defense Into Attack: Snapshots Of A Changing Medtech Market And How To Respond

 
• By 

Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.

AI Agents Set To Reshape Biopharma’s Workforce And Operations

 
• By 

While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.